Altoida’s core product is a precision neurology platform that uses AI to analyze a proprietary 10-minute set of digital test activities delivered via augmented reality on a smartphone or tablet to capture cognitive and functional changes. The AR-based tests simulate activities of daily living to detect Mild Cognitive Impairment and Alzheimer’s earlier and more accurately than existing methods; the platform has received FDA Breakthrough Device Designation. The company says its technology is intended to accelerate and improve drug development, research, and clinical care for neurological diseases and to validate applications across Parkinson’s and schizophrenia. Altoida plans to invest in medical, scientific, engineering, and commercial teams, and to expand its US and global intellectual property and regulatory portfolios. The platform is supported by more than 20 years of scientific research and aims to address the large and growing global burden of Alzheimer’s and related dementias. Altoida is based in Washington, D.C. Altoida develops an FDA-cleared and CE Mark–approved medical device and brain health data platform that uses AI, ML and AR to collect functional and cognitive digital biomarkers. The company leverages smart device sensors and interactive tasks (asking patients to hide and seek virtual objects) to analyze visuospatial and executive function and detect ‘‘micro-errors’’ as prognostic and diagnostic biomarkers. Altoida’s technology is used by researchers, patients and physicians to detect Mild Cognitive Impairment due to Alzheimer’s disease in patients 62+ years old between six and ten years prior to symptom onset. The platform and methodology have been validated in more than 12 peer-reviewed publications and over 200 independent studies. Altoida says the new financing will support expansion in the US, Japan, Europe and Brazil. The company is led by Dr. Richard Fischer and has offices in Houston, San Diego and Lucerne, Switzerland. Altoida develops an FDA-cleared and CE Mark-approved medical device and brain-health data platform that objectively assesses cognitive and everyday functions prior to symptom onset. Its product leverages artificial intelligence, machine learning and augmented reality to collect functional and cognitive biomarkers. The platform analyzes visuospatial and executive function through a battery of three tests that ask patients to hide and seek virtual objects in physical space. Altoida has been validated in more than 12 peer-reviewed publications and over 200 independent studies and is used in clinics across the US, Europe and Brazil. The company raised $6.3M in a Series A and intends to use the capital to expand its global presence with an immediate focus on commercialization in the US and EU markets. Altoida maintains offices in Houston, San Diego and Lucerne, Switzerland.

Total raised

$20M

Funding rounds

3

Latest round

Series A

Latest activity

Mar 2022